Eli Lilly posts record revenue but stock lags, with $1,500 target possible by 2027 on pipeline success.
Eli Lilly reported a historic 48% revenue growth in Q2 2026, driven by strong sales of Mounjaro and raised its full-year EPS guidance. Despite these results, the stock trades below its 52-week high due to concerns over U.S. price declines and acquisi...
